13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
37 檔
1.5%
According to the latest 13F quarterly dataset, Alphabet Inc. managed an equity portfolio of $99.1B at the end of Q3 2025, spanning 37 distinct U.S. exchange-listed positions.
In Q3 2025, Alphabet Inc. adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 6 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASTS | Ast Spacemobile Inc | Stock-Tech | 18.22% | -17.66% | — | |
| 2 | PL | Planet Labs Pbc | Stock-Industrials | 17.21% | -23.35% | — | |
| 3 | ARM | Arm Holdings Plc-adr | Stock-Tech | 11.52% | -6.69% | — | |
| 4 | ✓ | Stock-Other | 8.22% | — | -23.75% | ||
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 8.01% | -7.41% | — | |
| 6 | FRSH | Freshworks Inc-cl A | Stock-Other | 7.92% | -3.07% | — | |
| 7 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 5.20% | -1.66% | — | |
| 8 | GTLB | Gitlab Inc-cl A | Stock-Tech | 5.10% | -1.39% | — | |
| 9 | PATH | Uipath Inc - Class A | Stock-Tech | 3.91% | -1.86% | — | |
| 10 | PRME | Prime Medicine Inc | Stock-Other | 3.81% | -1.38% | +9.96% | |
| 11 | DXCM | Dexcom Inc | Stock-Healthcare | 2.90% | — | — | |
| 12 | MAZE | Maze Therapeutics Inc | Stock-Other | 2.60% | -0.99% | — | |
| 13 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.36% | -0.61% | — | |
| 14 | FIG | Figma Inc-cl A | Stock-Other | 0.46% | -0.11% | — | |
| 15 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.45% | -0.27% | — | |
| 16 | SANA | Sana Biotechnology Inc | Stock-Other | 0.41% | -0.19% | — | |
| 17 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.38% | -0.13% | — | |
| 18 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 19 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.34% | -0.36% | — | |
| 20 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.32% | -0.18% | — | |
| 21 | VERA | Vera Therapeutics Inc | Stock-Other | 0.29% | -0.23% | — | |
| 22 | LYEL | Lyell Immunopharma Inc | Stock-Other | 0.20% | -0.15% | — | |
| 23 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.10% | — | — | |
| 24 | WGS | Genedx Holdings CORP | Stock-Other | 0.10% | — | — | |
| 25 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.09% | — | — | |
| 26 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.08% | — | — | |
| 27 | BRNS | Barinthus Biotherapeutics Pl | Stock-Other | 0.08% | — | — | |
| 28 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.07% | -0.05% | — | |
| 29 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.06% | -0.02% | EXIT | |
| 30 | HYPR | Hyperfine Inc | Stock-Other | 0.05% | -0.02% | — | |
| 31 | EXK | Exact Sciences CORP | Stock-Materials | 0.05% | — | — | |
| 32 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.05% | -0.02% | — | |
| 33 | GUTS | Fractyl Health Inc | Stock-Other | 0.04% | — | — | |
| 34 | ALEC | Alector Inc | Stock-Other | 0.02% | — | — | |
| 35 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.01% | — | — | |
| 36 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.01% | — | — | |
| 37 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PL | Planet Labs Pbc | +10.4% | — | Unchanged |
| 2 | ASTS | Ast Spacemobile Inc | +5.3% | — | Unchanged |
| 3 | PRME | Prime Medicine Inc | +1.9% | +9.96% | Add |
| 4 | MAZE | Maze Therapeutics Inc | +0.9% | — | Unchanged |
| 5 | TEM | Tempus Ai Inc-cl A | +0.5% | — | Unchanged |
| 6 | SANA | Sana Biotechnology Inc | +0.1% | — | Unchanged |
| 7 | DNTH | Dianthus Therapeutics Inc | +0.1% | — | Unchanged |
| 8 | RLAY | Relay Therapeutics Inc | +0.1% | — | Unchanged |
| 9 | TSHA | Taysha Gene Therapies Inc | 0% | — | Unchanged |
| 10 | SPRO | Spero Therapeutics Inc | 0% | — | Unchanged |
| 11 | TNYA | Tenaya Therapeutics Inc | 0% | — | Unchanged |
| 12 | GLUE | Monte Rosa Therapeutics Inc | 0% | — | Unchanged |
| 13 | HYPR | Hyperfine Inc | 0% | — | Unchanged |
| 14 | ALEC | Alector Inc | 0% | — | Unchanged |
| 15 | FULC | Fulcrum Therapeutics Inc | 0% | — | Unchanged |
| 16 | RGEN | Repligen CORP | — | — | Unchanged |
| 17 | TCRX | Tscan Therapeutics Inc | 0% | — | Unchanged |
| 18 | BRNS | Barinthus Biotherapeutics Pl | 0% | — | Unchanged |
| 19 | GUTS | Fractyl Health Inc | 0% | — | Unchanged |
| 20 | EXK | Exact Sciences CORP | 0% | — | Unchanged |
| 21 | QNCX | Quince Therapeutics, Inc. | 0% | — | Unchanged |
| 22 | OSCR | Oscar Health Inc - Class A | 0% | — | Unchanged |
| 23 | FHTX | Foghorn Therapeutics Inc | 0% | — | Unchanged |
| 24 | AUTL | Autolus Therapeutics PLC | 0% | — | Unchanged |
| 25 | WGS | Genedx Holdings CORP | 0% | — | Unchanged |
| 26 | BEAM | Beam Therapeutics Inc | -0.1% | — | Unchanged |
| 27 | VERA | Vera Therapeutics Inc | -0.1% | — | Unchanged |
| 28 | ✓ | -0.3% | -23.75% | Trim | |
| 29 | PATH | Uipath Inc - Class A | -0.7% | — | Unchanged |
| 30 | RVMD | Revolution Medicines Inc | -1.3% | — | Unchanged |
| 31 | DXCM | Dexcom Inc | -1.6% | — | Unchanged |
| 32 | ARM | Arm Holdings Plc-adr | -1.8% | — | Unchanged |
| 33 | GTLB | Gitlab Inc-cl A | -3% | — | Unchanged |
| 34 | FRSH | Freshworks Inc-cl A | -6.6% | — | Unchanged |
| 35 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 36 | BBOT | Bridgebio Oncology Therapeut | — | NEW | New buy |
| 37 | CRWD | Crowdstrike Holdings Inc - A | — | EXIT | Sold out |
| 38 | FIG | Figma Inc-cl A | — | NEW | New buy |
| 39 | DM* | Desktop Metal Inc-a | — | EXIT | Sold out |
| 40 | LYEL | Lyell Immunopharma Inc | — | NEW | New buy |
| 41 | LYEL | Lyell Immunopharma, Inc. | — | EXIT | Sold out |
| 42 | KRON1USD | Kronos Bio Inc | — | EXIT | Sold out |
| 43 | RANI | Rani Therapeutics Holdings-a | — | EXIT | Sold out |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 37 disclosed positions in Q3 2025.
During Q3 2025, Alphabet Inc.'s top holdings by market value included ASTS (18.2%)、PL (17.2%)、ARM (11.5%). The largest single position, ASTS, represented 18.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASTS, PL, ARM) accounted for 1.5% of total reported equity market value during Q3 2025.
Top New Position Initiated
BBOT
市值: $32.7M
Top Position Liquidated / Trimmed
VERVE THERAPEUTICS INC
前期市值: $56.4M
In Q3 2025, Alphabet Inc. made 11 total portfolio adjustments, initiating 3 new buys, adding to 1 positions, trimming 1 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.